Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02187-18. doi: 10.1128/AAC.02187-18. [Epub ahead of print] Review.

PMID:
30670413
2.

Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups.

Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG, Riccobene T, Carrothers TJ, Das S.

Clin Transl Sci. 2018 Sep 17. doi: 10.1111/cts.12585. [Epub ahead of print]

PMID:
30221827
3.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov.

PMID:
30061279
4.

Avibactam Pharmacokinetic/Pharmacodynamic Targets.

Nichols WW, Newell P, Critchley IA, Riccobene T, Das S.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02446-17. doi: 10.1128/AAC.02446-17. Print 2018 Jun. Review.

5.

Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.

Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS.

J Clin Pharmacol. 2017 Mar;57(3):345-355. doi: 10.1002/jcph.809. Epub 2016 Sep 27.

PMID:
27510635
6.

Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.

Riccobene TA, Pushkin R, Jandourek A, Knebel W, Khariton T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5849-57. doi: 10.1128/AAC.02755-15. Print 2016 Oct.

7.

Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Mawal Y, Critchley IA, Riccobene TA, Talley AK.

Expert Rev Clin Pharmacol. 2015;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30. Review.

PMID:
26420166
8.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

9.

Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.

Beresford E, Biek D, Jandourek A, Mawal Y, Riccobene T, Friedland HD.

Expert Rev Clin Pharmacol. 2014 Mar;7(2):123-35. doi: 10.1586/17512433.2014.884457. Epub 2014 Feb 5. Review.

PMID:
24494793
11.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

12.

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6348-50. doi: 10.1128/AAC.01748-13. Epub 2013 Sep 16.

13.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.

Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.

J Clin Pharmacol. 2013 Nov;53(11):1155-67. doi: 10.1002/jcph.153. Epub 2013 Aug 14.

PMID:
23907740
14.

Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval.

Riccobene TA, Rekeda L, Rank D, Llorens L.

Antimicrob Agents Chemother. 2013 Apr;57(4):1777-83. doi: 10.1128/AAC.02352-12. Epub 2013 Jan 28.

15.

Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.

Riccobene TA, Su SF, Rank D.

Antimicrob Agents Chemother. 2013 Mar;57(3):1496-504. doi: 10.1128/AAC.02134-12. Epub 2013 Jan 7.

16.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Biek D, Critchley IA, Riccobene TA, Thye DA.

J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv9-16. doi: 10.1093/jac/dkq251. Review.

PMID:
21115457
17.

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V.

Br J Cancer. 2005 Apr 25;92(8):1430-41.

18.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G.

Cancer Immunol Immunother. 2005 Jun;54(6):535-47. Epub 2004 Dec 8.

PMID:
15592670
19.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR.

Arthritis Rheum. 2003 Nov;48(11):3253-65.

20.

Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.

Riccobene TA, Miceli RC, Lincoln C, Knight Y, Meadows J, Stabin MG, Sung C.

J Nucl Med. 2003 Mar;44(3):422-33.

21.

Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys.

Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, Hirsch J, Mahoney A, Carrell J, Boyd E, Grzegorzewski KJ.

Pharm Res. 2002 Nov;19(11):1720-9.

PMID:
12458679
22.

Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans.

Sung C, Parry TJ, Riccobene TA, Mahoney A, Roschke V, Murray J, Gu ML, Glenn JK, Caputo F, Farman C, Odenheimer DJ.

AAPS PharmSci. 2002;4(2):E8.

23.

Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice.

Parry TJ, Riccobene TA, Strawn SJ, Williams R, Daoud R, Carrell J, Sosnovtseva S, Miceli RC, Poortman CM, Sekut L, Li Y, Fikes J, Sung C.

J Pharmacol Exp Ther. 2001 Feb;296(2):396-404. Erratum in: J Pharmacol Exp Ther 2001 May;297(2):827.

PMID:
11160623
24.

Modeling activation and desensitization of G-protein coupled receptors provides insight into ligand efficacy.

Riccobene TA, Omann GM, Linderman JJ.

J Theor Biol. 1999 Sep 21;200(2):207-22.

PMID:
10504286
25.

Threshold and graded response behavior in human neutrophils: effect of varying G-protein or ligand concentrations.

Riccobene TA, Waller A, Hoffman JF, Linderman JJ, Omann GM.

Biochemistry. 1998 Aug 18;37(33):11534-43.

PMID:
9708989
26.

Interconverting receptor states at 4 degrees C for the neutrophil N-formyl peptide receptor.

Hoffman JF, Keil ML, Riccobene TA, Omann GM, Linderman JJ.

Biochemistry. 1996 Oct 8;35(40):13047-55.

PMID:
8855940

Supplemental Content

Loading ...
Support Center